TY - CHAP M1 - Book, Section TI - Cancer Chemotherapy A1 - Katzung, Bertram G. A1 - Kruidering-Hall, Marieke A1 - Tuan, Rupa Lalchandani A1 - Vanderah, Todd W. A1 - Trevor, Anthony J. PY - 2021 T2 - Katzung & Trevor's Pharmacology: Examination & Board Review, 13e AB - Cancer chemotherapy remains a challenging area of pharmacology. On the one hand, use of cytotoxic anticancer drugs produces high rates of cure of a few cancers, which, without chemotherapy, result in extremely high mortality rates (eg, acute lymphocytic leukemia in children, testicular cancer, and Hodgkin lymphoma). On the other hand, some types of cancer are minimally affected by currently available drugs. Furthermore, as a group, the cytotoxic anticancer drugs are more toxic than any other drug class and thus their benefit must be carefully weighed against their risks. Many of the available drugs are cytotoxic agents that act on all dividing cells, cancerous or normal. The ultimate goal in cancer chemotherapy is to use advances in cell biology to develop targeted therapies that selectively affect specific cancer cells. This area is one of the most rapidly expanding fields in drug development. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/11/03 UR - accessmedicine.mhmedical.com/content.aspx?aid=1180558914 ER -